Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
OPERATING EXPENSES:
Research and development	$ 15,920	$ 11,353	$ 31,282	$ 18,237
General and administrative	11,336	8,175	21,394	14,893
Total operating expenses	27,256	19,528	52,676	33,130
LOSS FROM OPERATIONS:	(27,256)	(19,528)	(52,676)	(33,130)
OTHER INCOME (EXPENSE), NET:
Other income, net	240	1	374	2
Foreign exchange gains (losses)	1,958	(550)	3,291	(1,193)
Benefit from R&D tax credit	4,077	2,558	6,999	4,115
Total other income, net	6,275	2,009	10,664	2,924
Loss before income taxes	(20,981)	(17,519)	(42,012)	(30,206)
Income tax expense	(56)	(9)	(196)	(37)
Net loss	(21,037)	(17,528)	(42,208)	(30,243)
Other comprehensive (loss) income:
Foreign exchange translation adjustment	(17,134)	(355)	(24,327)	1,633
Comprehensive loss	$ (38,171)	$ (17,883)	$ (66,535)	$ (28,610)
Net loss per share - basic (in dollars per share)	$ (0.50)	$ (0.44)	$ (1.00)	$ (0.79)
Net loss per share - diluted (in dollars per share)	$ (0.50)	$ (0.44)	$ (1.00)	$ (0.79)
Weighted average ordinary shares outstanding - basic (in shares)	42,474,987	39,802,532	42,110,161	38,194,822
Weighted average ordinary shares outstanding - diluted (in shares)	42,474,987	39,802,532	42,110,161	38,194,822